|
|||||
|
|
Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection |
|
| Authors: | Smith Patrick F Ogundele Abayomi Forrest Alan Wilton John Salzwedel Karl Doto Judy Allaway Graham P Martin David E |
| Affiliation: | Hoffman-La Roche Inc, Clinical Pharmacology, Nutley, NJ 07110-1199, USA. Patrick.smith@roche.com |
| Abstract: | |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ | |